| # | Title | Journal | Year | Citations |
|---|
| 1 | Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution | Nature | 2017 | 1,287 |
| 2 | Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2017 | 604 |
| 3 | Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial | Lancet Oncology, The | 2016 | 356 |
| 4 | Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial | Lancet Oncology, The | 2017 | 256 |
| 5 | EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment | Annals of Oncology | 2015 | 230 |
| 6 | Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial | Lancet, The | 2020 | 226 |
| 7 | Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis | Cancer | 2012 | 222 |
| 8 | Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis | European Urology | 2016 | 207 |
| 9 | Incidence and survival of malignant bone sarcomas in England 1979–2007 | International Journal of Cancer | 2012 | 196 |
| 10 | Five-Day Oral Etoposide2 Treatment for Advanced Small-Cell Lung Cancer: Randomized Comparison With Intravenous Chemotherapy | Journal of the National Cancer Institute | 1997 | 194 |
| 11 | Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology | European Urology | 2017 | 174 |
| 12 | Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials | Annals of Oncology | 2012 | 166 |
| 13 | Harnessing the immune system in glioblastoma | British Journal of Cancer | 2018 | 138 |
| 14 | Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy | BJU International | 2007 | 130 |
| 15 | Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial | Journal of the National Cancer Institute | 2009 | 126 |
| 16 | A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma | Clinical Cancer Research | 2016 | 125 |
| 17 | Prevalence and Significance of Asymptomatic Venous Thromboembolic Disease Found on Oncologic Staging CT | American Journal of Roentgenology | 2007 | 123 |
| 18 | Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials | European Journal of Cancer | 2011 | 116 |
| 19 | Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib | Cancer | 2015 | 89 |
| 20 | Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer | Clinical Cancer Research | 2020 | 77 |
| 21 | Management of osteosarcoma | Current Treatment Options in Oncology | 2006 | 69 |
| 22 | Radiation-induced bowel injury: the impact of radiotherapy on survivorship after treatment for gynaecological cancers | British Journal of Cancer | 2013 | 68 |
| 23 | Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’ | Annals of Oncology | 2018 | 67 |
| 24 | Osteosarcoma: The Same Old Drugs or More? | Journal of Clinical Oncology | 2008 | 62 |
| 25 | The evolution of lung cancer and impact of subclonal selection in TRACERx | Nature | 2023 | 62 |
| 26 | Nose and paranasal sinus tumours: United Kingdom National Multidisciplinary Guidelines | Journal of Laryngology and Otology | 2016 | 58 |
| 27 | Dabrafenib and trametinib in BRAFV600E mutated glioma | CNS Oncology | 2017 | 58 |
| 28 | Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe | Cancers | 2020 | 58 |
| 29 | The role of interferons in the treatment of osteosarcoma | Pediatric Blood and Cancer | 2010 | 57 |
| 30 | Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer | Thorax | 2008 | 54 |
| 31 | OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer | Health Technology Assessment | 2016 | 53 |
| 32 | Pituitary Carcinoma in a Patient with an SDHB Mutation | Endocrine Pathology | 2017 | 50 |
| 33 | Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup | European Journal of Cancer | 2012 | 42 |
| 34 | The evolution of non-small cell lung cancer metastases in TRACERx | Nature | 2023 | 41 |
| 35 | National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer | International Journal of Radiation Oncology Biology Physics | 2017 | 38 |
| 36 | Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution | Sarcoma | 2006 | 36 |
| 37 | Uterine sarcomas—Recent progress and future challenges | European Journal of Radiology | 2011 | 35 |
| 38 | Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma | CNS Oncology | 2017 | 35 |
| 39 | Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: A double blind study | Medical Oncology and Tumor Pharmacotherapy | 1986 | 35 |
| 40 | Survival Outcomes and Prognostic Factors in Glioblastoma | Cancers | 2022 | 33 |
| 41 | Update on first-line treatment of advanced ovarian carcinoma | International Journal of Women's Health | 2013 | 32 |
| 42 | A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI | BMC Cancer | 2014 | 32 |
| 43 | Use of teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients | Journal of Hospital Infection | 1987 | 31 |
| 44 | Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer | Lung Cancer | 2008 | 30 |
| 45 | Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer | Gynecologic Oncology | 2020 | 30 |
| 46 | T-cell lymphomas in adults: A clinicopathological study of eighteen cases | Journal of Pathology | 1987 | 29 |
| 47 | Experiences and Preferences for End-of-Life Care for Young Adults with Cancer and Their Informal Carers: A Narrative Synthesis | Journal of Adolescent and Young Adult Oncology | 2017 | 28 |
| 48 | Patient-reported outcomes in metastatic castration-resistant prostate cancer | Nature Reviews Clinical Oncology | 2016 | 27 |
| 49 | A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol | BMC Cancer | 2020 | 25 |
| 50 | Imaging of the gastrointestinal complications of systemic chemotherapy | Clinical Radiology | 2009 | 24 |
